[1] Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in2008-2012[J]. Neuro Oncol, 2015, 17(Suppl 4): iv1-iv62. [2] Tsvetkov P, Coy S, Petrova B, et al.Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 375(6586): 1254-1261. [3] Sheftel AD, Stehling O, Pierik AJ, et al.Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis[J]. Proc Natl Acad Sci USA, 2010, 107(26): 11775-11780. [4] Xiao C, Yang L, Jin L, et al.Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer[J]. Front Genet, 2022, 13: 962028. [5] Zhang C, Zeng Y, Guo X, et al.Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker[J]. Front Genet, 2022, 13: 923737. [6] Zhang WT, Gong YM, Zhang CY, et al.A Novel Cuprotosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients[J]. Biomed Res Int, 2022, 2022: 9196540. [7] Zhang Z, Ma Y, Guo X, et al.FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma[J]. Front Pharmacol, 2021, 12: 749134. [8] Zhang Z, Zeng X, Wu Y, et al.Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma[J]. Front Immunol, 2022, 13: 925618. [9] Bruni D, Angell HK, Galon J.The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680. [10] Hinshaw DC, Shevde LA.The Tumor Microenvironment Innately Modulates Cancer Progression[J]. Cancer Res, 2019, 79(18): 4557-4566. [11] La Vecchia S, Sebastián C.Metabolic pathways regulating colorectal cancer initiation and progression[J]. Semin Cell Dev Biol, 2020, 98: 63-70. |